Visión generalGráficoNoticiasTraderScreen

ING Knock-Out RO/  DE000NG8RW00  /

Frankfurt Zertifikate
13/11/2024  16:36:11 Diferencia-0.060 Bid17:14:36 Ask17:14:36 Subyacente Precio de ejercicio Fecha de expiración Tipo de opción
12.140EUR -0.49% -
Volumen de oferta: -		 -
Tamaño/ Volumen/ Formato de Ask: -		 ROCHE I 170.4238 CHF 31/12/2078 Call
TeleTrader 23/10 Roche's Q3 sales up 6% to 15.1B Swiss francs
Newsfile Corp 11/10 JRR Marketing Announces Launch of New Book "5 Ways to Get Strangers to Want to Buy Your Stuff" to He...
Newsfile Corp 02/10 First Phosphate Corp. communique la publication d'une note de recherche universitaire relative aux g...
GlobeNewswire 26/08 First Patient Dosed with LIXTE’s LB-100 in New Clinical Trial to Treat Colorectal Cancer, Collaborat...
GlobeNewswire 19/08 LIXTE Biotechnology Provides Update On Recent Activities and Developments
TeleTrader 25/07 Europe lower premarket as earnings pour in
TeleTrader 25/07 Roche's H1 sales at 29.85 billion Swiss francs
GlobeNewswire 27/06 Arch Biopartners Announces GMP Manufacturing of Cilastatin Drug Product
GlobeNewswire 18/06 Arch Biopartners Announces University of Calgary Ethics Approval to Proceed with Phase II Trial for ...
GlobeNewswire 14/06 LIXTE Biotechnology Holdings to Collaborate with Roche and Netherlands Cancer Institute in New Colon...
GlobeNewswire 11/06 Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D ...
TeleTrader 27/05 Roche shuffles its executive committee
TeleTrader 16/05 Roche notes progress in obesity drug trial
GlobeNewswire 09/05 US Neurologists Report Route of Administration as a Critical Factor when Evaluating Future Parkinson...
GlobeNewswire 07/05 Enable Injections Expands Strategic Partnership with Roche
TeleTrader 24/04 Roche's logs 14.4 billion Swiss francs in Q1 sales
GlobeNewswire 03/04 UHN Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Inju...
GlobeNewswire 02/04 Arch Biopartners Adds Three New Clinical Sites into the Phase II Trial for LSALT Peptide Targeting C...
GlobeNewswire 14/03 Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides C...
GlobeNewswire 26/02 Codexis Enters Exclusive Licensing Agreement for Newly Engineered Double-Stranded DNA Ligase with Ro...
GlobeNewswire 21/02 REPARE ALERT: Bragar Eagel & Squire, P.C. is Investigating Repare Therapeutics Inc. on Behalf of Rep...
TeleTrader 01/02 Roche's 2023 sales increase 1% to 58.7B Swiss francs
GlobeNewswire 29/01 Carmot Therapeutics Announces Completion of Acquisition by Roche
GlobeNewswire 03/01 US Neurologists Optimistic Regarding the Huntington’s Disease Treatment Pipeline, Emphasizing Haltin...
GlobeNewswire 03/01 Arch Biopartners Receives Approval from the Turkish Ministry of Health to Proceed with Phase II Tria...